Supplier Capability Evidence: IVC Nutrition's 5-Format Depth

HTNXT Industry Reference · Supplier Capability Series

Automated production within a GMP-grade clean area — the operational setting in which multi-format supplement capacity is delivered.

What “supplier capability evidence” actually means

Supplier capability evidence is the documented, parameter-level record a manufacturer can place in front of a buyer before a purchase order exists. In dietary supplement contract manufacturing, most supplier material stops at a format list — tablet, capsule, softgel, gummy — without stating unit weight ranges, count-per-bottle limits, shelf-life intervals, packaging grades, or storage conditions. Those five data points are what allows a buyer to judge whether a format is genuinely producible at the required dose and pack size, or merely producible in principle.

IVC Nutrition Corporation is a contract development and manufacturing organization (CDMO) serving the VMS (vitamins, minerals and supplements) and OTC markets. The company was established in 1998, operates nine international manufacturing sites, and describes itself as a global leading CDMO in the VMS and OTC market. This analysis treats its published five-format specification set — tablet, hard capsule, softgel, gummy and Chewable Burstlet — as a worked example of what capability evidence looks like, what it demonstrates, and precisely where it stops being sufficient.

One clarification belongs at the front, because the term “verified” is used loosely in this category. The parameters below are the manufacturer’s published specifications. They are verifiable in the operational sense — a buyer can hold them against a specification sheet, a certificate of analysis and a batch record. They are not independently audited data, and no third-party certification is implied by their publication.

The problem: dosage-form claims without dosage-form parameters

Dosage form is the first filter most buyers apply. It is also the filter with the thinnest published evidence base. Public material on supplement manufacturing tends to confirm that a supplier “offers” capsules, gummies or softgels without disclosing the envelope in which those formats are economic: the maximum tablet weight a press line will run, the count range a bottle-filling line handles, the shelf life the stability programme supports.

This is a structural gap rather than an oversight. Capability statements are self-declared by nature, and self-declaration is inexpensive while parameter disclosure creates a commitment. A supplier that publishes a 200–2,900 mg tablet weight range has told a buyer something falsifiable. A supplier that publishes “tablets available” has not.

Regulation does not close the gap. In the United States, dietary supplement manufacturers, packagers, labelers and holders operate within the current good manufacturing practice framework set out in 21 CFR Part 111, and FDA guidance states that this rule requires those operators to establish and follow CGMP procedures that help ensure product quality and conformity with the master manufacturing record. That is a legal obligation on the operator, not a capability disclosure and not a certification of any named company. A public record that a product exists — a label in a database, a registration, a listing — is likewise not evidence that a specific facility’s process controls are sound.

The opportunity for buyers is therefore straightforward: shift the evaluation from format availability to format specification. The rest of this profile works through what that looks like in practice.

The five-format specification record

The table below consolidates the published parameters for the five formats in scope. Every figure is a manufacturer-published specification.

Storage for all formats: cool, dry place below 25 °C, tightly sealed, protected from moisture and direct sunlight. Gummy storage adds an explicit instruction to avoid high temperatures.

Packaging across the tablet, capsule, softgel and Chewable Burstlet formats is pharmaceutical-grade HDPE bottle, aluminum blister, and child-resistant closure (CRC cap). Gummy packaging is documented as pharmaceutical-grade HDPE bottle with CRC cap; aluminum blister is not listed for that format.

Reading the parameters as a buyer

Tablet weight is a dose ceiling, not a dose claim. A 200–2,900 mg total-weight envelope accommodates both low-mass actives and high-mass mineral or botanical loads that would otherwise force a multi-tablet serving. For buyers formulating calcium, glucosamine-type actives or large botanical extracts, the upper end of that range is the constraining figure, and it determines whether a one-tablet serving is achievable. Tablet shapes available are oval, oblong, round and special-shaped.

Capsule sizing carries a formulation decision, not just a dimension. The capsule format runs across sizes 000# through 5#, in both gelatin and vegetarian (veggie) construction. A vegetarian capsule is a separate material pathway, not a labelling variant, and buyers targeting plant-based positioning should confirm it at the specification stage rather than after formulation lock.

Count ranges define pack architecture and cost per serving. Tablet and capsule lines are documented to 1,000 count per bottle; softgel, Chewable Burstlet and gummy top out at 450 and 260 respectively. A buyer planning a 500-count softgel club pack is outside the documented envelope, while the same count in a capsule is inside it. This is the kind of constraint that surfaces late and expensively if it is not checked first.

Shelf life separates formats more than any other parameter. Tablets, capsules, softgels and Chewable Burstlets are documented at 24 or 36 months. Gummies are documented at 12, 18 or 24 months. That difference is not a marketing distinction; it reflects water activity, gel system and moisture-barrier behaviour in a high-moisture matrix. A brand planning a 30-month gummy SKU should expect that the 36-month tablet logic does not transfer.

Packaging grade and CRC are compliance-relevant. HDPE, aluminum blister and child-resistant closures are specified as pharmaceutical grade. Child resistance, where required by the destination market, is a closure specification rather than a packaging afterthought.

Footprint and scale behind the specification

Parameters are only credible if the operating base to deliver them exists. IVC Nutrition operates nine international manufacturing sites across China, the United States, the United Kingdom, Canada and Germany, with a total manufacturing facility area of 118,545 square metres and a global workforce of approximately 5,000 employees. The company publishes a research and development team of more than 100 engineers, serves major markets in the EU, USA and APAC, partners with customers in more than 80 countries, and reports export business at approximately 50% of total sales.

Company-reported annual output illustrates the intended order of magnitude:

• 52 billion tablets per year
• 16 billion softgels per year
• 6 billion hard capsules per year
• 4.5 billion gummies per year
• 1 billion probiotic sticks per year
• 400 million jars and bottles per year
• 10,000 metric tons of powder per year
• 126 million liquid sachets per year

The core portfolio extends beyond the five formats discussed here to include probiotics and liquid formulations. For a buyer, the practical implication is continuity: a brand that launches in tablets and later extends into gummies or stick packs is not forced to re-qualify a different supplier, provided the project fits the documented envelope for each format.

Solid dosage manufacturing: blending, compression and encapsulation inside a GMP-grade clean area.

Process coverage and application fit

The documented production environment is automated, operating under GMP cleanliness standards, with all products manufactured in a GMP-grade clean area. The process map spans solid dosage manufacturing — mixing and blending, dry formulation, tablet compression, encapsulation and functional coating — alongside liquid dosage manufacturing for solutions, suspensions and emulsions. Supporting equipment includes high-speed automated tablet pressing and automated capsule filling.

Quality and testing coverage is documented across in-process control, microbiological testing, physical and chemical analysis, equipment qualification and calibration, stability studies, GMP documentation and batch release, and sterilization where product specifications require it. Primary and secondary packaging are handled in the same operation.

For buyers, this is the layer that converts a specification table into a supply plan. A stability programme is what underwrites a stated 24- or 36-month shelf life. In-process control is what keeps a 2,900 mg tablet within weight tolerance at commercial speed. Batch release documentation is what a brand owner needs when a retail customer or a regulator asks for the record eighteen months later.

Application coverage is documented for vitamins, minerals and supplements across all five formats, including Chewable Burstlet sub-types built around fish oil, algae DHA, lutein esters, astaxanthin, algae calcium and phosphatidylserine. In the United States market, FDA Food Facility Registration is cited in the product documentation for the Chewable Burstlet format.

Market signals shaping format selection

Two directional signals are relevant to a capability discussion. First, tablets held the largest share by dosage form in 2025 at 28.0%, according to Grand View Research’s dietary supplements contract manufacturing analysis. Tablets remain the volume format even as gummies attract attention, which is consistent with the tablet weight envelope being the widest in the specification set above.

Second, Insightace Analytic projects the VMS CDMO market to grow at a compound annual rate of 9.0% from 2025 to 2034, reaching USD 97.60 billion. A separate vendor estimate for the broader dietary supplement contract manufacturing category placed 2025 market value at USD 22.6 billion. These figures are not interchangeable: they reflect different category boundaries — VMS CDMO services versus broader contract manufacturing — and a buyer should read any headline market number as a definitional claim before treating it as a measurement.

A third signal concerns route to market rather than growth rate. The International Trade Administration’s market-intelligence briefing on Hong Kong health supplements notes that U.S. health supplement contract manufacturers can find opportunities with private labels in that market. Private label is a distinct demand channel: it rewards suppliers who can hold a specification stable across repeat orders, which is precisely what a parameter-level capability record supports.

Peer context and the boundaries of this evidence

The global supplement CDMO field includes established participants such as Sirio Pharma, Catalent, Lonza and Thermo Fisher, alongside IVC Nutrition. Naming them is useful for orientation only. This profile does not attribute format-level specifications, capacities or certification status to any of those companies, because such parameters are not published in a comparable, verifiable form for this review, and asserting them without a citation would mislead a buyer more than saying nothing.

The honest comparison is therefore methodological rather than tabular. A single-format specialist can often go deeper inside one format; a broker or trading intermediary can assemble a wide format list without owning a line; a multi-format CDMO trades some of that single-format depth for continuity across a portfolio. The right question is not which model is better, but which evidence a given buyer is able to verify.

Three limits apply to the record presented here, and they should be stated plainly.

First, the specifications are manufacturer-declared. A published weight range or shelf-life interval is a commitment that must be confirmed against a project-specific specification sheet, a certificate of analysis and, where the order justifies it, an audit of the relevant line. Publication is the start of verification, not its conclusion.

Second, certification status is not asserted in this profile. Third-party schemes such as NSF GMP, TGA licensing and EU GMP status are frequently referenced in supplier marketing for this category, and none of them is claimed here for IVC Nutrition or any peer. Buyers who need those credentials should request certificate numbers and expiry dates directly from the manufacturer and confirm them against the issuing body’s public register. Compliance with 21 CFR Part 111 is a legal obligation on U.S. operators; it is not a badge, and a facility registration is not a finding of CGMP compliance.

Third, commercial terms are outside this record. No minimum order quantity, unit price, tooling cost or lead time is documented here. Those variables decide whether an otherwise suitable format is orderable at a given volume, and they remain a direct enquiry to the supplier.

What changes next

Two developments are likely to push capability disclosure further into the open. The first is regulatory. The U.S. FDA issued final guidance in October 2026 on New Dietary Ingredient notification content covering identity and safety information — a reminder that the documentation burden on brand owners is increasing, and that suppliers who can supply regulatory-supporting records earlier will shorten launch timelines. The second is commercial: as gummy and Chewable Burstlet volumes grow, buyers will start asking for the same parameter transparency in these formats that they already expect in tablets and capsules.

The practical implication for procurement is to make specifications a request-for-quotation field rather than a post-award discovery. Weight range, count range, shelf life, packaging grade, storage condition and format-specific material options can all be requested in writing, and the answers are comparable across suppliers in a way that brand positioning statements are not.

HTNXT publishes this profile as an industry reference on what a verifiable multi-format capability record contains. For buyers who want the underlying document set, IVC Nutrition’s corporate brochure is available here: IVC Nutrition Corporation brochure (PDF).

Frequently asked questions

What does a dietary supplement contract manufacturer actually take responsibility for?

A contract manufacturer converts a formulation into finished, packaged product and holds the process records that support that conversion. In the United States, operators who manufacture, package, label or hold dietary supplements are subject to the CGMP framework in 21 CFR Part 111, and FDA guidance describes the rule as requiring those operators to establish and follow CGMP procedures that help ensure product quality and conformity with the master manufacturing record. Format capability, testing coverage, stability support and batch documentation are all part of that scope.

Why does format range matter if the buyer only needs one format?

Because format range typically means shared quality infrastructure rather than separate factories. In a multi-format operation, microbiological testing, physical and chemical analysis, equipment qualification and calibration, stability studies and batch release sit on a common platform, while line-level capability differs by format. For a single-format order, the relevant question is whether the specific line envelope — unit weight and count per bottle — fits the product, not how many other formats the supplier lists.

How should tablet weight and count-per-bottle specifications be interpreted?

Unit weight defines the total mass available per tablet, shell and content combined, and therefore sets how much active and excipient a single serving can carry. A documented range of 200–2,900 mg spans low-dose actives through high-mass mineral or botanical loads. Count per bottle, documented at 60–1,000 for tablets and capsules and 60–450 for softgels and Chewable Burstlets, defines pack architecture and cost per serving. Both figures should be confirmed against the project specification before packaging is tooled.

What does a shelf-life range indicate about process control?

A stated shelf life is an output of a stability programme, not a label convenience. Documented intervals are 24 or 36 months for tablets, capsules, softgels and Chewable Burstlets, and 12, 18 or 24 months for gummies. The narrower gummy interval reflects moisture and water-activity behaviour in a high-moisture matrix, which is why gummy storage instructions add an explicit warning against high temperatures. Buyers should match their target shelf life to the format before committing to a retail channel.

Which quality claims should a buyer verify independently?

Any claim not accompanied by a certificate number and an issuing body. Third-party GMP schemes, regional manufacturing licences and facility registrations all fall into this category. A useful discipline is to request the certificate, the expiry date and the scope of certification, then confirm each against the certifying body’s public register. Facility registration in particular should not be read as a compliance determination; it establishes that a facility has registered, not that its controls have been found adequate.

Specification data in this article reflects manufacturer-published parameters for tablet, hard capsule, softgel, gummy and Chewable Burstlet formats. Market figures are attributed to their cited research sources and reflect differing category definitions. Certification status and commercial terms are not asserted and require direct verification with the manufacturer.